{"id":1112,"date":"2024-09-20T09:12:00","date_gmt":"2024-09-20T09:12:00","guid":{"rendered":"https:\/\/www.arcgroup.io\/uxbridge\/?p=1112"},"modified":"2024-10-08T08:33:17","modified_gmt":"2024-10-08T08:33:17","slug":"daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment","status":"publish","type":"post","link":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/","title":{"rendered":"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment"},"content":{"rendered":"\n<!-- Back button -->\n<div class=\"back-button-block__container\">\n\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/community\/\" class=\"back-button-block\">\n\t\t<svg class=\"back-button-block__arrow\" width=\"13\" height=\"13\">\n\t\t\t<use xlink:href=\"#small-arrow\"><\/use>\n\t\t<\/svg>\n\t\tBack to Community\t<\/a>\n<\/div>\n\n\n\n<section class=\"feature-banner\" id=\"block_e0ced189909195711e2d34a1dc7498c1\"> \n    <div class=\"feature-banner__container\">\n            <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-300x188.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-1024x642.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-768x482.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-1000x627.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(max-width: 768px) 768px, (max-width: 1024px) 1024px, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg\" \/>\n            <\/picture>\n\n    <\/div>\n<\/section>\n\n\n<h2 class=\"wp-block-post-title\">Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment<\/h2>\n\n\n    <ul class=\"ed-post-categories\">\n                    <li class=\"arc-purple\">\n                <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/category\/corporate\/\">Corporate<\/a>\n            <\/li>\n                    <li class=\"arc-orange\">\n                <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/category\/news\/\">News<\/a>\n            <\/li>\n            <\/ul>\n\n\n\n<p><strong>Daiichi Sankyo, whose UK base is at ARC Uxbridge, has received approval from the National Institute for Health and Care Excellence (NICE) for Vanflyta to be used for certain cases of acute myeloid leukaemia (AML).<\/strong><\/p>\n\n\n\n<p>The drug has been recommended for routine NHS commissioning in England and Wales and is the first selective FLT3 inhibitor to be approved for use in the UK.<\/p>\n\n\n\n<p>Approximately 18,000 people are diagnosed with AML, a type of blood cancer that starts from young white blood cells in the bone marrow, every year in Europe.<\/p>\n\n\n\n<p>Commenting on the recommendation, Haran Maheson, head of UK oncology and vice president, Daiichi Sankyo UK, said:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;We are proud to have worked with NICE and NHS England to secure the first reimbursement for [Vanflyta] following health technology assessment in Europe. UK patients with newly diagnosed FLT3-ITD positive AML can now receive a selective targeted therapy for their disease for the first time.&#8221;<\/p>\n<\/blockquote>\n\n\n\n<p>Sharing a similar sentiment, Colin Dyer, chief executive of UK charity Leukaemia Care, said:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>&#8220;We welcome the decision by NICE to approve this treatment&#8230; Patients with FLT3-ITD mutations have an increased risk of relapse with standard treatments, so another targeted treatment option for such patients is important for clinicians to tailor treatment plans to their patients effectively.&#8221;<\/p>\n<\/blockquote>\n\n\n    <section class=\"news-archive \" id=\"block_a17227578e9071b4910f620a0c1559f5\">\n                    <div class=\"ed-container news-archive__title ed-archive-header__title ed-archive-header__title--large\">\n                <div class=\"ed-row\">\n                    <div class=\"ed-col ed-col__half\">\n                        \n                            <h3>More News<\/h3>\n                                            <\/div>\n                    <div class=\"ed-col ed-col__half\">\n                                                    <a href=\"https:\/\/www.arcgroup.io\/uxbridge\/community\/\" target=\"\">\n                                View all news &rarr;\n                            <\/a>\n                                            <\/div>\n                <\/div>\n            <\/div>\n                <div class=\"ed-container\">\n            <div class=\"ed-row\">\n                \n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-300x207.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-1024x706.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-768x530.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-1000x690.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/211021-BLAST-Uxbridge-Business-Park-036-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2026\/01\/19\/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline\/\" target=\"_self\">\n\t\t\t\tAmgen acquires Dark Blue Therapeutics, bolstering oncology pipeline\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/07\/11\/arc-uxbridge-named-workspace-of-the-year-at-the-2025-hustle-awards\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-300x200.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-1024x683.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-768x512.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter-1000x667.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/08\/DSC07846-scaled-ezgif.com-webp-to-jpg-converter.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/07\/11\/arc-uxbridge-named-workspace-of-the-year-at-the-2025-hustle-awards\/\" target=\"_self\">\n\t\t\t\tARC Uxbridge, named Workspace of the Year at the 2025 Hustle Awards\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n\n<article class=\"news-block ed-col ed-col__third\">\n\t<div class=\"news-block__inner\">\n\t\t<!-- Thumbnail -->\n\t\t<figure class=\"wp-block-post-featured-image\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/03\/25\/arc-uxbridge-outperforms-5-year-average-uptake-for-the-area\/\">\n\t\t\t\t    <picture class=\"\">\n        <source srcset=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-scaled.jpg 2560w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-300x200.jpg 300w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-1024x682.jpg 1024w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-768x512.jpg 768w, https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-1000x666.jpg 1000w\" type=\"image\/jpeg\" sizes=\"(min-width: 1200px) 34vw, (min-width: 768px) 50vw, 100vw\">\n        <img decoding=\"async\" loading=\"lazy\" src=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/03\/ARC-Uxbridge-scaled.jpg\" \/>\n            <\/picture>\n\n\n\t\t\t\t<!-- Terms -->\n\t\t\t\t\t\t\t\t\t<div class=\"news-block__categories\">\n\t\t\t\t\t\t\t\t\t\t\t\t<div class=\"arc-orange\">News<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<\/a>\n\t\t<\/figure>\n\n\t\t<!-- Title -->\n\t\t<div class=\"news-block__inner-title\">\n\t\t\t<a href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2025\/03\/25\/arc-uxbridge-outperforms-5-year-average-uptake-for-the-area\/\" target=\"_self\">\n\t\t\t\tBrookfield&#8217;s ARC Uxbridge Campus Outperforms 5-year average uptake for the area following surge in high-profile leases\t\t\t<\/a>\n\t\t<\/div>\n\t<\/div>\n<\/article>\n            <\/div>\n        <\/div>\n    <\/section>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo, whose UK base is at ARC Uxbridge, has received approval from the National Institute for Health and Care Excellence (NICE) for Vanflyta to be used for certain cases of acute myeloid leukaemia (AML). The drug has been recommended for routine NHS commissioning in England and Wales and is the first selective FLT3 inhibitor [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":1115,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[30,22],"tags":[],"class_list":["post-1112","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo, whose UK base is at ARC Uxbridge, has received approval from the National Institute for Health and Care Excellence (NICE) for Vanflyta to be used for certain cases of acute myeloid leukaemia (AML). The drug has been recommended for routine NHS commissioning in England and Wales and is the first selective FLT3 inhibitor [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"ARC Uxbridge\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-20T09:12:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-08T08:33:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1606\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"nataliegelder\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"nataliegelder\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\"},\"author\":{\"name\":\"nataliegelder\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\"},\"headline\":\"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment\",\"datePublished\":\"2024-09-20T09:12:00+00:00\",\"dateModified\":\"2024-10-08T08:33:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\"},\"wordCount\":220,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg\",\"articleSection\":[\"Corporate\",\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\",\"name\":\"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment\",\"isPartOf\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg\",\"datePublished\":\"2024-09-20T09:12:00+00:00\",\"dateModified\":\"2024-10-08T08:33:17+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg\",\"width\":2560,\"height\":1606},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.arcgroup.io\/uxbridge\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#website\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/\",\"name\":\"ARC Uxbridge\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\"},\"alternateName\":\"ARC Uxbridge\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.arcgroup.io\/uxbridge\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#organization\",\"name\":\"ARC Uxbridge\",\"alternateName\":\"ARC Uxbridge\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png\",\"contentUrl\":\"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png\",\"width\":2084,\"height\":2085,\"caption\":\"ARC Uxbridge\"},\"image\":{\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3\",\"name\":\"nataliegelder\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g\",\"caption\":\"nataliegelder\"},\"url\":\"https:\/\/www.arcgroup.io\/uxbridge\/blog\/author\/nataliegelder\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment","og_description":"Daiichi Sankyo, whose UK base is at ARC Uxbridge, has received approval from the National Institute for Health and Care Excellence (NICE) for Vanflyta to be used for certain cases of acute myeloid leukaemia (AML). The drug has been recommended for routine NHS commissioning in England and Wales and is the first selective FLT3 inhibitor [&hellip;]","og_url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/","og_site_name":"ARC Uxbridge","article_published_time":"2024-09-20T09:12:00+00:00","article_modified_time":"2024-10-08T08:33:17+00:00","og_image":[{"width":2560,"height":1606,"url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg","type":"image\/jpeg"}],"author":"nataliegelder","twitter_card":"summary_large_image","twitter_misc":{"Written by":"nataliegelder","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#article","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/"},"author":{"name":"nataliegelder","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3"},"headline":"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment","datePublished":"2024-09-20T09:12:00+00:00","dateModified":"2024-10-08T08:33:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/"},"wordCount":220,"commentCount":0,"publisher":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg","articleSection":["Corporate","News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/","url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/","name":"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment","isPartOf":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg","datePublished":"2024-09-20T09:12:00+00:00","dateModified":"2024-10-08T08:33:17+00:00","breadcrumb":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#primaryimage","url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg","contentUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2024\/09\/julia-koblitz-RlOAwXt2fEA-unsplash-1-scaled.jpg","width":2560,"height":1606},{"@type":"BreadcrumbList","@id":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/2024\/09\/20\/daiichi-sankyo-gets-go-ahead-for-acute-myeloid-leukaemia-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.arcgroup.io\/uxbridge\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo gets go-ahead for acute myeloid leukaemia treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#website","url":"https:\/\/www.arcgroup.io\/uxbridge\/","name":"ARC Uxbridge","description":"","publisher":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization"},"alternateName":"ARC Uxbridge","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.arcgroup.io\/uxbridge\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#organization","name":"ARC Uxbridge","alternateName":"ARC Uxbridge","url":"https:\/\/www.arcgroup.io\/uxbridge\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/","url":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png","contentUrl":"https:\/\/www.arcgroup.io\/uxbridge\/wp-content\/uploads\/sites\/3\/2025\/06\/ARC-SUBBRANDS-LOGOS-03-UXBRIDGE-1.png","width":2084,"height":2085,"caption":"ARC Uxbridge"},"image":{"@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/3f1cd3ed5ba88a032f304b0bce8d3ee3","name":"nataliegelder","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.arcgroup.io\/uxbridge\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3fb7b427d3598506c2b50eb193a7e9ae080d5643e4b602a6b3b58a96341add54?s=96&d=mm&r=g","caption":"nataliegelder"},"url":"https:\/\/www.arcgroup.io\/uxbridge\/blog\/author\/nataliegelder\/"}]}},"_links":{"self":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts\/1112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/comments?post=1112"}],"version-history":[{"count":0,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/posts\/1112\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/media\/1115"}],"wp:attachment":[{"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/media?parent=1112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/categories?post=1112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.arcgroup.io\/uxbridge\/wp-json\/wp\/v2\/tags?post=1112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}